Ramelteon demonstrates high binding affinity at MT1 and MT2 receptor subtypes with substantially lower affinity at MT3, and no measurable binding at a broad panel of other receptor binding sites including benzodiazepine, dopamine, opiate, and ion channel targets. This selectivity profile makes Ramelteon a standard tool compound in research examining specifically melatonergic receptor contributions to circadian rhythm and sleep-wake cycle pathway signalling, without the confounding receptor activities associated with non-selective melatonin ligands.

Rodent circadian models measuring wheel-running activity rhythms and SCN neuronal firing patterns are standard experimental systems for studying Ramelteon's proposed phase-shifting and entrainment properties, typically examining the magnitude and direction of circadian phase shifts induced by compound administration at different circadian time points relative to vehicle controls. Ex vivo SCN electrophysiology preparations complement these in vivo approaches by allowing direct measurement of neuronal firing rate modulation following compound exposure.

Ramelteon's indanyl-furan scaffold is structurally distinct from native melatonin's indole-based structure, a difference studied in comparative structure-activity relationship research examining how the two structural frameworks interact with MT1/MT2 receptor binding sites. Ramelteon's scaffold confers significantly higher binding affinity at MT1 and MT2 relative to native melatonin, making it a useful reference compound for distinguishing high-affinity versus low-affinity melatonin receptor binding contributions in circadian research models.